

Synthesis and selectivity of 1-methoxycarbonylmethyl-3-arylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-ones binding for CNS benzodiazepine receptors

N.A. Burenkova, V.I. Pavlovsky*, I.A. Oleinich, I.A. Boyko, S.Yu. Makan,
A.G. Artemenko, V.E. Kuz'min

A.V. Bogatsky Physico-Chemical Institute of the NAS of Ukraine
86 Lustdorfska doroga, Odesa, 65080, Ukraine

Summary. Earlier, the methoxycarbonylmethyl fragment at the 1-position and the nitrophenylamine fragment at the 3-position of the 1,4-benzodiazepine ring, on the base of the QSAR analysis of series of 1,4-benzodiazepin-2-one derivatives [1], have been shown to gave compounds with increased affinity for peripheral benzodiazepine receptors (PBR). The 3-arylamino derivatives of 1-methoxycarbonylmethyl-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one were proposed for the directed synthesis as a promising high selective ligands of PBR. The target compounds were synthesized through the condensation of 1-methoxycarbonylmethyl-3-chloro-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one with substituted anilines. Affinities of synthesized compounds for the CNS benzodiazepine receptors of peripheral (PBR) and central (CBR) types were determined by the radioligand method *in vitro*. Selective PBR ligand with a high affinity — 1-methoxycarbonylmethyl-3-(2'-nitro)phenylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one, **7 (MX-1785)**, $K_i(\text{PBR})=19.1$ nM, $K_i(\text{CBR})>10000$ nM) was found among the studied compounds.

Keywords: 1,3-substituted 1,2-dihydro-3H-1,4-benzodiazepin-2-ones, affinity, benzodiazepine receptors, selectivity, QSAR analysis.

Introduction. There are central (CBR) [2], and peripheral (PBR) [3] benzodiazepine receptors. CBR are presented exclusively in the central nervous system. They are located at pre- and postsynaptic membranes of neurons and mediate the classic effects of benzodiazepines [4]. PBR were initially discovered in the kidney [5], then in many organs and tissues, including the CNS [3]. Originally PBR were considered as one of the CBR subtypes, but later they were identified as an individual class of receptors due to their unique structure, cell localization and performance of physiological functions media-

ted by them [3, 6, 7]. Peripheral benzodiazepine receptors are 5-transmembrane 169-amino acid polypeptides with a molecular weight of 18 kDa, which are localized mainly on the mitochondrial outer membrane of peripheral tissues and glial cells of the CNS [3, 6].

Recent years the results of studies have shown that PBR are an important component of the so-called mitochondrial permeability transition pore (MPTP) involved in regulation of ions concentration, pH, and the volume of mitochondria as well as in Ca^{2+} ions transfer [6, 8].

The exact physiological function of PBR is not yet fully understood, but a wide range of pharmacological activities, such as anticonvulsant, anxiolytic, immunomodulating, and cardiovascular, has been related to its activation [3, 7, 9].

In particular, there is growing number of

* Corresponding author.

Tel.: +38048-7659230; fax: +38048-7659602

E-mail address: Victor_pavlovsky@mail.ru

experimental evidence that high affinity PBR ligands stimulate the synthesis of neurosteroids in glial cells. PBR mediate the delivery of cholesterol to the inner mitochondrial membrane where it is oxidized by cytochrome P450_{sc} (side chain cleavage) to pregnenolone — parent compound of endogenous steroids [6-11]. Some neurosteroids [pregnenolone sulfate, 3 α ,21-dihydroxy-5 α -pregnan-20-one (3 α ,5 α -THDOC), 3 α -hydroxy-5 α -pregnan-20-one (3 α ,5 α -THPROG), and dehydroepiandrosterone] are known to modulate GABAergic and glutamatergic neurotransmission [8, 11-13]. Numerous studies show that such neuropathologic states as multiple sclerosis, Wernicke's encephalopathy, Alzheimer's disease, Huntington's disease, epilepsy, stroke and stress are associated with the PBR expression [3, 7, 11, 14-16]. The highest PBR density is observed in many tumor types such as brain, hepatic, liver glial, and mammary tumors, adenocarcinoma, breast carcinoma, and ovarian, and colorectal cancers — all of them have showed a selective increase in PBR density compared with non-transformed tissue [17, 18]. In some cases the grade of PBR over-expression appears to be correlated with the malignancy of the tumor and mortality of patients [18, 19].

PBR-specific ligands are considered both as new intracellular targets of action [20] of radiological diagnostic imaging agents [21] and receptor-mediated drug carriers [22, 23], which can selectively deliver anticancer agents into tumors [24, 25]. The development of new strategies for molecular design and synthesis of high affinity and selective PBR ligands with a given pharmacological properties is the top issue for medical and bioorganic chemistry, experimental and clinical medicine.

There are several classes of PBR ligands available including 1,4-benzodiazepines (Ro 5-4864 [26]; gidazepam, MX-633 [27]), isoquinoline carboxamides (PK 11195) [28], 2-aryl-3-indolacetamides (FGIN-1-27) [29], N-phenoxyphenyl-N-isopropoxybenzylacetamides (DAA1097) [30], pyrrolbenzoxazepines (OXA-17f) [31], 1,3,4-benzotriazepines (MX-1189) [32] and some others (Fig. 1).

We have conducted the search for selective highly active PBR ligands among 1- and 3-substituted derivatives of 1,2-dihydro-3H-1,4-benzodi-




Fig. 1. The structures of some PBR ligands.


azepin-2-one. Earlier [27], we studied affinity of gidazepam (MX-633) for CBR and PBR. Gidazepam has an original range of pharmacological activity and demonstrated a prominent anxiolytic effect with poor myorelaxant and hypnotic side effects [33]. The results of the radioligand binding analysis showed [27] that gidazepam has a 3-fold higher affinity for PBR than for CBR; IC₅₀ values are of 710 nM and 2200 nM, respectively.

Our data demonstrate that substitutions of bromine atom at the 7-position of the gidazepam template either with a chlorine atom or a methyl group led to the decrease in affinity for PBR. The substitution of the hydrazine fragment with methoxy group and the presence of (2'-chloro)phenyl substituent at the 5-position of the benzodiazepine ring contributed to an unexpected increase in affinity for PBR [27].

We have reported earlier [34], that some of 3-arylidene-7-bromo-5-(2'-chloro)phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-ones are selective PBR ligands. A selective PBR ligand 3-(4'-chloro)benzylidene-7-bromo-5-(2'-chloro)phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one (MX-1735) is especially interesting among these ligands. We have shown that the presence of either chlorine or bromine atom in a *para*-position of the 3-benzylidene fragment plays a crucial role in the manifestation of selectivity and affinity for PBR versus CBR.

Later, in [1] we have reported the results of QSAR analysis of 1- and 3-substituted 1,2-dihydro-3H-1,4-benzodiazepin-2-ones with the use of the method of simplex representation of molecular structure [35, 36] and the «Dragon» program [37, 38]. Based on the interpretation of obtained highly adequate models, it was found that the presence of methoxycarbonylalkyl group at the 1-

Scheme 1
 Synthesis of 1-methoxycarbonylmethyl-3-aryl-
 amino-1,2-dihydro-3H-1,4-benzodiazepin-2-ones



position of the benzodiazepine cycle, is an important descriptor to ensure recognition of the studied 1,2-dihydro-3H-1,4-benzodiazepin-2-ones by PBR. In the series of 3-amino-1,2-dihydro-3H-1,4-benzodiazepin-2-ones, compounds containing nitroaniline substituent at the 3-position of the benzodiazepine cycle have the higher affinity for PBR. By the results of the QSAR analysis [1], molecular design and computer screening were conducted for new selective PBR ligands, 1,4-benzodiazepin-2-one derivatives, which are recommended for directed synthesis.

Thus, the aim of our study was the synthesis of new 1,3-substituted derivatives of 1,4-benzodiazepin-2-one and the estimation of their affinity and selectivity for CBR and PBR in CNS.

Results and discussion. Synthesis of 1-methoxycarbonylmethyl-3-aryl-amino-1,2-dihydro-3H-1,4-benzodiazepin-2-ones (**6-9**) (Table 1) has been carried out as follows.


1-Methoxycarbonylmethyl-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one-4-oxide (**1**) obtained according to [39] was used as an initial compound. 3-Acetoxy derivative **2** was obtained through the acylation of the compound **1** with acetyl chloride.

An attempt to obtain the final compounds **6-9** from the 3-acetoxy derivative **2** through the coupling with the corresponding arylamines was unsuccessful.

Saponification of the compound **2** was carried out with sodium hydroxide in methanol. At equimolar ratio of the base and substrate, selective saponification of 3-acetoxy group with the formation of **3** was occurred, and at the double excess of the base — saponification of two ether groups with the formation of **4**.

Through the coupling of the 3-hydroxy derivative **3** with thionyl chloride, 3-chloro derivative **5** has been obtained, followed by its conden-

Table 1
 Properties of 1,3-substituted 1,2-dihydro-3H-1,4-benzodiazepin-2-ones (**2-9**)
 and their affinity for CNS benzodiazepine receptors



№	R ¹	R ²	mp, °C	Yield, %	Colour	Formula	Found %			Affinity (K _i , nM)	
							Calculated %	C	N	H	CBR
2	CH ₃	OCOCH ₃	188-192	80	White	C ₂₀ H ₁₇ BrN ₂ O ₅	53.95 53.90	6.29 6.33	3.85 3.79	-	-
3	CH ₃	OH	168-172	65	White	C ₁₈ H ₁₅ BrN ₂ O ₄	53.62 53.68	6.95 6.93	3.75 3.77	-	-
4	H	OH	265-269 (destr.)	60	White	C ₁₇ H ₁₃ BrN ₂ O ₄	52.46 52.41	7.20 7.24	3.37 3.28	-	-
6	CH ₃	NHC ₆ H ₅	178-182	85	White	C ₂₄ H ₂₀ BrN ₃ O ₃	60.26 60.22	8.78 8.83	4.21 4.19	>10000	740.0±180.0
7 , MX-1785	CH ₃	NH-(2-NO ₂ C ₆ H ₄)	242-244	65	Yellow	C ₂₄ H ₁₉ BrN ₄ O ₅	55.08 55.13	10.71 10.66	3.66 3.73	>10000	19.1±3.0
8	CH ₃	NH-(3-NO ₂ C ₆ H ₄)	186-190	75	Yellow	C ₂₄ H ₁₉ BrN ₄ O ₅	55.08 55.03	10.71 10.68	3.66 3.70	>10000	360.4±41.0
9	CH ₃	NH-(4-NO ₂ C ₆ H ₄)	240-244	70	Yellow	C ₂₄ H ₁₉ BrN ₄ O ₅	55.08 55.04	10.71 10.77	3.66 3.61	>10000	87.3±10.1




Fig. 2. Affinity of 1-methoxycarbonylmethyl-3-arylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-ones for CNS PBR.

sation either with aniline (at room temperature) or with *ortho*-, *meta*-, *para*-nitroaniline (refluxed in chloroform for 5–6 hours) and obtaining of final 3-arylamino derivatives **6–9**.

The structures of synthesized compounds have been proved by the methods of mass spectrometry, infrared spectroscopy and ¹H NMR spectroscopy. Properties of compounds and their affinities for the central and peripheral benzodiazepine CNS receptors are shown in the Table 1.

In the IR spectra of compounds **6–9** the absorption bands corresponding to the vibration of carbonyl group bonds (C=O) within the region 1660–1690 cm⁻¹, and vibrations of C=O bonds in methoxycarbonylmethyl fragment within the region 1690–1730 cm⁻¹, are observed.

The absorption bands corresponding to the vibrations of NH-group for the compounds **6, 8–9** are within the region 3360–3380 cm⁻¹, and for the compound **7 (MX-1785)** it is shifted to the long-wave region and can be observed at 3320 cm⁻¹ resulting from the formation of intramolecular hydrogen bonds between the hydrogen atoms of NH-group and oxygen atoms of nitro group.

The bands corresponding to vibrations of C=C and C=N bonds are in the 1580–1600 cm⁻¹ region.

In the ¹H NMR spectra of compounds **6–9**, the signals of aromatic protons are within the region 7.26–8.11 ppm, and the signals of protons of methoxycarbonyl group are within the region 3.62–3.72 ppm. A proton signal at the C (3) atom is observed at 4.26–6.04 ppm. The NH proton signal is in the aromatic protons region.

Affinity of compounds **6–9** for benzodiazepine CNS receptor was determined by the radioligand method *in vitro*. Affinity was evaluated by the values of inhibition constants (K_i) which




Fig. 3. The dependence of inhibition (I , %) of the specific binding of the [³H]PK 11195 radioligand to PBR on the concentrations of PK 11195 and compound **7 (MX-1785)**, respectively. According to the abscissa axis — logarithms of the concentrations of PK 11195 and compound **7 (MX-1785)**, to the ordinate axis — % of inhibition of specific binding of the [³H]PK 11195 radioligand to CNS PBR.

were estimated by the ability of the investigated compounds to displace competitively radioligands (CBR antagonist [³H]flumazenil and PBR antagonist [³H]PK 11195) from their specific binding sites in benzodiazepine receptors of central and peripheral types of sinaptosomal and mitochondrial membrane fractions of rats brain, respectively.

It was found that the 3-aniline substituent containing compound **6** is characterized by low affinity for PBR with a value of $K_i=740.0$ nM. Changing the position of the nitro group in the 3-aniline fragment of molecule 1-methoxycarbonylmethyl-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one resulted in the preparation of high-affinity compounds and revealed the following trends in changes of affinity of compounds for PBR (Fig. 2): the compound containing *ortho*-nitroaniline substituent (**7, MX-1785**, $K_i=19.1$ nM) at the 3-position of benzodiazepine cycle is bind to the PBR of CNS better than the *para*- and *meta*-nitroaniline derivatives (**9**, $K_i=87.3$ nM, and **8**, $K_i=360.4$ nM, respectively).

This group of compounds has high selectivity of binding to PBR (values K_i of binding of these substances to CBR > 10000 nM).

In the series of studied 1-methoxycarbonylmethyl-3-arylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-ones, the high affinity compound **7 (MX-1785)** was found. This compound has affinity for PBR comparable to that of radioligand [³H]PK 11195 (Fig. 3). The

above-mentioned compound is of interest for pharmacological research.

Experimental section. Materials and methods.

The IR spectra were recorded on a Specord 75-IR (solutions in CHCl_3). Mass spectra were obtained using the method of electron ionization on mass spectrometer MX-1321 (ionization voltage 70 eV, temperature of the ionization chamber is 200 °C).

^1H NMR spectra were recorded on a Bruker spectrometer at 300 MHz frequency, in CDCl_3 , internal standard TMS, at 25 °C. Thin layer chromatography was performed on plates Silufol UV-254, in benzene : chloroform : hexane (1 : 1 : 3) system, development with UV-light at $\lambda=254$ nm.

Methods for the synthesis of 1,2-dihydro-3H-1,4-benzodiazepin-2-one derivatives.

1-Methoxycarbonylmethyl-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one-4-oxide (1). The compound was obtained according to the procedure described in [39].

1-Methoxycarbonylmethyl-3-acetoxy-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one (2). To a solution of compound **1** (30 g, 0.075 mol) in benzene (100 ml), the acetyl chloride (10.6 ml, 0.15 mol) was added. The mixture was heated at 40 °C for 40 minutes. Residue was filtered and crystallized from methanol. Yield 26 g (78 %), mp 142-144 °C. Mass spectrum, m/z (%): 444 (10) $[\text{+H}]^+$. ^1H NMR spectrum (CDCl_3), δ , ppm: 3.62 s (3H, $\text{CH}_2\text{COOCH}_3$), 6.04 s (1H, $\text{C}^3\text{-H}$), 7.42-7.72 m (8H, H_{arom}). IR spectrum, ν , cm^{-1} (CHCl_3): 1720 (COOCH_3), 1690 (C=O).

1-Methoxycarbonylmethyl-3-hydroxy-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one (3). To a mixture of compound **2** (1.0 g, 1.9 mmol) in methanol (20 ml), the solution of NaOH (75 mg, 1.9 mmol) in H_2O (6 ml) was added. The reaction mixture was stirred for 3 minutes, and then chloroform (30 ml) and water (30 ml) were added. Chloroform layer was separated, washed with water to pH 7, dried over magnesium sulphate, and then chloroform was evaporated. The resulting oil was triturated with ethanol (5 ml) to give white solid. Yield 0.66 g (78 %), mp 138-142 °C. Mass spectrum m/z (%): 403 (43) $[\text{+H}]^+$. ^1H NMR spectrum (CDCl_3), δ , ppm: 3.69 s (3H, $\text{CH}_2\text{COOCH}_3$), 5.09 d ($J=9.65$ Hz, 1H, $\text{C}^3\text{-H}$), 7.41-7.70 m (8H, H_{arom}). IR spectrum, ν , cm^{-1} (CHCl_3): 1720 (COOCH_3), 1680 (C=O).

1-Carboxymethyl-3-hydroxy-7-bromo-5-

phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one (4). To a solution of compound **2** (1.0 g, 1.9 mmol) in methanol, the solution of NaOH (0.15 g, 3.8 mmol) in H_2O (6 ml) was added. The reaction mixture was stirred for 10 minutes, and product precipitated with water. Then it was crystallized from ethanol. Yield 0.5 g (68 %), mp 232-235 °C. Mass spectrum m/z (%): 389 (27) $[\text{+H}]^+$. ^1H NMR spectrum (CDCl_3), δ , ppm: 5.10 d ($J=9.65$ Hz, 1H, $\text{C}^3\text{-H}$), 7.42-7.73 m (8H, H_{arom}), IR spectrum, ν , cm^{-1} (CHCl_3): 1680 (C=O).

1-Methoxycarbonylmethyl-3-chloro-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one (5). The mixture of compound **3** (1.0 g, 2.4 mmol) and thionyl chloride (10 ml) were placed into a flask and left for 10 hours. Excess of thionyl chloride was evaporated under reduced pressure. Then absolute chloroform (20 ml) was added, and solvent was evaporated, process was repeated three times to remove thionyl chloride completely. The compound **5** was used in further synthesis without isolation.

1-Methoxycarbonylmethyl-3-phenylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one (6). The mixture of compound **5** (1.0 g, 2.3 mmol), aniline (0.42 g, 4.6 mmol) and chloroform (20 ml) were placed into a flask. The mixture was left for 10 hours. Precipitate of aniline hydrochloride was filtered, chloroform layer was washed with water (5x20 ml), dried over magnesium sulphate. Solution was evaporated under reduced pressure, the residue was crystallized from benzene. Yield 0.8 g (73 %), mp 144-146 °C. Mass spectrum m/z (%): 479 (25) $[\text{+H}]^+$. ^1H NMR spectrum (CDCl_3), δ , ppm: 3.69 s (3H, $\text{CH}_2\text{COOCH}_3$), 5.16 d ($J=7.47$ Hz, 1H, $\text{C}^3\text{-H}$), 7.26-7.73 m (8H, H_{arom}). IR spectrum, ν , cm^{-1} (CHCl_3): 1690 (COOCH_3), 1660 (C=O), 3360 (N-H).

1-Methoxycarbonylmethyl-3-(2'-nitro)phenylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one (7, MX-1785). A mixture of compound **5** (1.0 g, 2.3 mmol) and *o*-nitroaniline (0.63 g, 4.6 mmol) in anhydrous chloroform (20 ml) was refluxed for 4 hours, then cooled to room temperature and washed with water (4x20 ml). The organic layer was dried over magnesium sulphate. The solvent was evaporated and the residue was crystallized from benzene. Yield 0.7 g (58 %), mp 223-226 °C. Mass spectrum m/z (%): 524 (11) $[\text{+H}]^+$. ^1H NMR spec-

trum (CDCl₃), δ , ppm: 3.71 s (3H, CH₂COOCH₃), 5.29 d ($J=6.23$ Hz, 1H, C³-H), 7.35-7.75 m (8H, H_{arom}). IR spectrum, ν , cm⁻¹ (CHCl₃): 1720 (COOCH₃), 1680 (C=O), 3320 (N-H).

1-Methoxycarbonylmethyl-3-(3'-nitro)phenylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one (8). The compound was obtained according to the procedure described for **7**. Yield 0.6 g (51 %), mp 223-226 °C. Mass spectrum m/z (%): 524 (43) [+H]⁺. ¹H NMR spectrum (CDCl₃), δ , ppm: 3.72 s (3H, CH₂COOCH₃), 5.22 d ($J=7.47$ Hz, 1H, C³-H), 7.30-7.76 m (8H, H_{arom}). IR spectrum, ν , cm⁻¹ (CHCl₃): 1730 (COOCH₃), 1680 (C=O), 3380 (N-H).

1-Methoxycarbonylmethyl-3-(4'-nitro)phenylamino-7-bromo-5-phenyl-1,4-benzodiazepin-2-one (9). The compound was obtained according to the procedure described for **7**. Yield 0.68 g (67 %), mp 214-216 °C. Mass spectrum m/z (%): 524 (100) [+H]⁺. ¹H NMR spectrum (CDCl₃), δ , ppm: 3.72 s (3H, CH₂COOCH₃), 5.21 d ($J=7.16$ Hz, 1H, C³-H), 7.35-8.11 m (8H, H_{arom}). IR spectrum, ν , cm⁻¹ (CHCl₃): 1720 (COOCH₃), 1680 (C=O), 3360 (N-H).

All experiments on animals were carried out in accordance with the experimental protocol for humane treatment for animals European Communities Council Directive of 24 November 1986 (86/609/EEC).

Study of affinity of synthesized compounds for CBR and PBR CNS.

The experiments were conducted in white nonpedigreed male rats (180-220 g) from the vivarium at Odessa State Medical University, with free access to water and food. The anesthetized animals were decapitated, then the cortex was quickly isolated on a cold. Experiment on radioligand binding was conducted with the use of the membranes synaptic fraction of rats brain, that was obtained similar to [40] and mitochondrial membranes fraction of rats brain obtained similar to [41]. Affinities of synthesized compounds for both central and peripheral benzodiazepine CNS receptors were determined by the radioligand method *in vitro*. Antagonist CBR [³H] flumazenil (3219 TBq/mol, «Du Pont NEN») and antagonist PBR [³H]PK 11195 (2775 TBq/mol, «Du Pont NEN») were used as radioligands.

The analysis of the interaction of compounds **6-9** with CBR and PBR was conducted according to the previously described methods [42, 43].

The affinity was evaluated on the ability of the compounds (1 μ M) to displace radioligands from sites of their specific binding to the receptors. For the most active compounds IC₅₀ values (concentration, when tested compound inhibits the receptor — radioligand specific binding by 50 %) were determined.


A total of eight concentrations within the range of 0.1 nM — 10 μ M were used to determine the value of IC₅₀. Each experimental point was obtained in sextets. The data are given as $M \pm m$, where M is mean value of three independent experiments, m is the standard mean error.

Calculation of IC₅₀ was conducted through the linearization of S-like curve. The calculation of inhibition constant K_i was determined using the Cheng-Prusoff equation [44]:

$$K_i = \frac{IC_{50}}{1 + \frac{[L]}{K_d}}$$

IC₅₀ — concentration of the tested ligand for the displacement of 50 % of the radioligand from the sites of its specific binding to receptor; [L] — the initial radioligand concentration; K_d — radioligand dissociation constant.

Conclusions. Ability of 1-methoxycarbonylmethyl-3-arylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-ones (**6-9**) for selective binding to CNS PBR was shown. A high affinity compound 1-methoxycarbonylmethyl-3-(2'-nitro)phenylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-on, **7 (MX-1785)**, K_i(PBR)=19.1 nM, K_i(CBR)>10000 nM) was revealed in series of investigated substances. Given compound is prospective for the pharmacological research. Among the investigated 1-methoxycarbonylmethyl-3-arylamino-7-bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-ones it was found the following trend concerning the influence of nitrogen group position in 3-aniline moiety on affinity for PBR:



The high affinity and selectivity of compound **MX-1785** designed by QSAR analysis indicate a possibility of further QSAR research for identification of selective and highly active PBR ligands in the series of 1,3-substituted 1,4-benzodiazepin-2-ones.

Надійшла в редакцію 24.12.2008 р.

**Синтез і селективність зв'язування з бенздіазепіновими рецепторами ЦНС
1-метоксикарбонілметил-3-ариламіно-7-бром-5-феніл-1,2-дигідро-3H-1,4-бенздіазепін-2-онів**

Н.О. Буренкова, В.І. Павловський, І.О. Олейніч, І.А. Бойко, С.Ю. Макань, А.Г. Артеменко, В.Є. Кузьмін

Фізико-хімічний інститут ім. О.В. Богатського НАН України
Люстдорфська дорога, 86, Одеса, 65080, Україна

Резюме. Раніше на підставі результатів QSAR-аналізу ряду похідних 1,4-бенздіазепін-2-ону [1] було показано, що наявність метоксикарбонілметильного фрагменту в положенні 1 і нітрофеніламінного фрагменту в положенні 3 1,4-бенздіазепінового циклу сприяють прояву високого афінітету до периферичних бенздіазепінових рецепторів (ПБДР). Для цілеспрямованого синтезу були запропоновані 3-ариламінопохідні 1-метоксикарбонілметил-7-бром-5-феніл-1,2-дигідро-3H-1,4-бенздіазепін-2-ону як перспективні високоафінні ліганди ПБДР. Конденсацією 1-метоксикарбонілметил-7-бром-3-хлор-5-феніл-1,2-дигідро-3H-1,4-бенздіазепін-2-ону із заміщеними анілінами синтезовано цільові сполуки. Методом радіолігандного аналізу в експериментах *in vitro* вивчено афінітет синтезованих сполук до бенздіазепінових рецепторів ЦНС периферичного (ПБДР) і центрального (ЦБДР) типів. У ряді досліджених сполук виявлено високоафінний і селективний ліганд ПБДР — 1-метоксикарбонілметил-3-(2'-нітро)феніламіно-7-бром-5-феніл-1,2-дигідро-3H-1,4-бенздіазепін-2-он, **7 (MX-1785, $K_i(\text{ПБДР})=19,1$ нМ, $K_i(\text{ЦБДР})>10000$ нМ).**

Ключові слова: 1,3-заміщені 1,2-дигідро-3H-1,4-бенздіазепін-2-они, афінітет, бенздіазепінові рецептори, селективність, QSAR-аналіз.

References

1. Tkachuk N.A., Makan S.Yu., Pavlovsky V.I., Andronati K.S., Artemenko A.G., Bondarover D.V., Kuz'min V.E., Khromov A.I. Synthesis, affinity and QSAR-analysis of potential ligands of CNS peripheral benzodiazepine receptors // *Voprosy Biologicheskoi, Meditsinskoi i Farmatsevticheskoi Khimii / Problems of Biological, Medical and Pharmaceutical Chemistry*. — 2008. — Vol. 2. — P. 20-25.
2. Barnard E.A., Skolnick P., Olsen R.W., Mohler H., Sieghart W., Biggio G., Braestrup C., Bateson A.N., Langer S.Z. International union of pharmacology. XV. Subtypes of γ -aminobutyric acid_A receptors: Classification on the basis of subunit structure and receptor function // *Pharmacol. Rev.* — 1998. — Vol. 50, No. 2. — P. 291-313.
3. Gavish M., Bachman I., Shoukrun R., Katz Y., Veenman L., Weisinger G., Weizman A. Enigma of the peripheral benzodiazepine receptor // *Pharmacol. Rev.* — 1999. — Vol. 51. — P. 629-650.
4. Burt D.R., Kamatchi G.L. GABA_A receptor subtypes: from pharmacology to molecular biology // *FASEB J.* — 1991. — Vol. 1, No. 5. — P. 2916-2923.
5. Braestrup C., Squires R. Specific benzodiazepine receptors in rat brain characterized by high-affinity [³H]diazepam binding // *Proc. Natl. Acad. Sci.* — 1977. — Vol. 74. — P. 3805-3809.
6. Casellas P., Galiègue S., Basile A.S. Peripheral benzodiazepine receptors and mitochondrial function // *Neurochem. International*. — 2002. — Vol. 40. — P. 475-468.
7. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapère J., Lindemann P., Norenberg M.D., Nutt D., Weizman A., Zhang M.-R., Gavish M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function // *Trends in Pharmacol. Sci.* — 2006. — Vol. 27, No. 8. — P. 402-409.
8. Lacapère J.-J., Papadopoulos V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis // *Steroids*. — 2003. — Vol. 68. — P. 569-585.
9. Veenman L., Papadopoulos V., Gavish M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response // *Curr. Pharm. Des.* — 2007. — Vol. 13. — P. 2385-2405.
10. Jamin N., Neumann J.-M., Ostuni M.A., Ngoc-Vu T.K., Yao Z.-X., Murail S., Robert J.-C., Giatzakis C., Papadopoulos V., Lacapère J.-J. Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor // *Mol. Endocrinol.* — 2005. — Vol. 19. — P. 588-594.
11. Papadopoulos V., Lecanu L., Brown R.C., Han Z., Yao Z.-X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders // *Neurosci.* — 2006. — Vol. 138. — P. 749-756.
12. Sanacora G., Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action // *CNS & Neurological Disorders — Drug Targets*. — 2007. — Vol. 6. — P. 127-140.
13. Wu F., Gibbs T.T., Farb D.H. Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor // *Mol. Pharmacol.* — 1991. — Vol. 40. — P. 333-336.
14. Hazell A.S., Normandin L., Nguyen B., Kennedy G. Upregulation of 'peripheral-type' benzodiazepine receptors in the globus pallidus in a sub-acute rat model of manganese neurotoxicity // *Neurosci. Lett.* — 2003. — Vol. 349. — P. 13-16.
15. Messmer K., Reynolds G.P. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease // *Neurosci. Lett.* — 1998. — Vol. 241. — P. 53-56.
16. Banati R.B., Newcombe J., Gunn R.N., Cagnin A., Turkheimer F., Heppner F., Prince G. The peripheral benzodiazepine binding site in the brain in multiple sclerosis. Quantitative in vivo imaging of glia of microglia as a measure of disease activity // *Brain*. — 2000. — Vol. 123. — P. 2321-2337.
17. Katz Y., Eitan A., Gavish M. Increase in peripheral benzodiazepine binding sites in colonic adenocarcinoma // *Oncology*. — 1990. — Vol. 47. — P. 139-142.
18. Veenman L., Levin E., Weisinger G., Leschiner S., Spanier I., Snyder S.H., Weizman A., Gavish M. Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines // *Biochem. Pharmacol.* — 2004. — Vol. 68. — P. 689-698.

19. *Hardwick M.* Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol // *Cancer Res.* — 1999. — Vol. 59. — P. 831-842.
20. *Weissman B.A., Raveh L.* Peripheral benzodiazepine receptors: on mice and human brain imaging // *J. Neurochem.* — 2003. — Vol. 84. — P. 432-437.
21. *Zhang M.-R., Maeda J., Ogawa M., Noguchi J., Ito T., Yoshida Y., Okauchi T., Obayashi S., Suhara T., Suzuki K.* Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for PET imaging of peripheral benzodiazepine receptor in primate brain // *J. Med. Chem.* — 2004. — Vol. 47. — P. 2228-2235.
22. *Margiotta N., Ostuni R., Ranaldo R., Denora N., Laquintana V., Trapani G., Liso G., Natile G.* Synthesis and characterization of a platinum(II) complex tethered to a ligand of the peripheral benzodiazepine receptor // *J. Med. Chem.* — 2007. — Vol. 50. — P. 1019-1027.
23. *Guo P., Ma J., Li S., Guo Z., Adams A.L., Gallo J.M.* Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model // *Cancer Chemother. Pharmacol.* — 2001. — Vol. 48. — P. 169-176.
24. *Kupczyk-Subotkowaka L., Siahhan T.J., Basile A., Friedman H.S., Higgins P.E., Song D., Gallo J.M.* Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate // *J. Med. Chem.* — 1997. — Vol. 40. — P. 1726-1730.
25. *Trapani G., Laquintana V., Latrofa A., Ma J., Reed K., Serra M., Biggio G., Liso G., Gallo J.M.* Peripheral benzodiazepine receptor ligand-melphalan conjugates for potential selective drug delivery to brain tumors // *Bioconjugate Chem.* — 2003. — Vol. 14. — P. 830-839.
26. *Marangos P.L., Pate J., Boulenger J.P., Clark-Rosenberg R.* Characterization of peripheral-type benzodiazepine binding sites in brain using [3H]Ro 5-4864 // *Mol. Pharmacol.* — 1982. — Vol. 22. — P. 26-32.
27. *Korkhov V.M., Tkachuk N.A., Makan S.Y., Pavlovsky V.I., Andronati S.A.* Affinities of gidazepam and its analogs for mitochondrial benzodiazepine receptors // *J. Recept. Signal Transduct. Res.* — 2002. — Vol. 22, No. 1-4. — P. 411-420.
28. *Fur G.L., Perrier M.L., Vaucher N., Imbault F., Flamier A., Uzan A., Renault C., Dubroeuq M.C., Gueremy C.* Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isquinolinecarboxamide I. In vitro studies // *Life Sci.* — 1983. — Vol. 32. — P. 1839-1847.
29. *Romeo E., Auta J., Kozikowski A.P., Ma A., Papadopoulos V., Puia G., Costa E., Guidotti A.* 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor // *J. Pharmacol. Exp. Ther.* — 1992. — Vol. 262. — P. 971-978.
30. *Okujama S., Chaki S., Yoshikawa R., Ogawa S., Suzuki Y., Okubo T., Nakazato A., Nagamine M., Tomisawa K.* Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA 1097 and DAA 1106 // *Life Sci.* — 1999. — Vol. 16. — P. 1455-1464.
31. *Campiani G., Nacci V., Fiorini I., Filippis M.P.D., Garofalo A., Ciani S.M., Greco G., Novellino E., Williams D.C., Zisterer D.M., Woods M.J., Mihai C., Manzoni C., Mennini T.* Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific «peripheral-type» benzodiazepine receptor ligands // *J. Med. Chem.* — 1996. — Vol. 39. — P. 3435-3450.
32. *Tkachuk N.A., Makan S.Yu., Vlasiuk S.V., Pavlovsky V.I., Andronati S.A.* Affinity of 1,3,4-benzotriazepin-2-one and -2-thione derivatives for the CNS benzodiazepine receptors // *Odessa National University Herald: Chemistry — Visnik Odeskogo Natsionalnogo Universitetu: Khimiya.* — 2005. — Vol. 10, No. 9. — P. 97-103.
33. *Andronati S.A., Voronina T.A., Golovenko N.M.* Pharmacology of Gidazepam. In *Gidazepam.* — Kiev: Naukova Dumka, 1992.
34. *Pavlovsky V.I., Bachinskii S.Yu., Tkachuk N.A., Makan S.Yu., Andronati S.A., Simonov Yu.A., Filippova I.G., and Gdaniec M.* Synthesis and structure of 3-arylidene and 3-hetarylidene-1,2-dihydro-3H-1,4-benzodiazepin-2-ones and their affinity toward CNS benzodiazepine receptors // *Chemistry of Heterocyclic Compounds.* — 2007. — Vol. 43, No. 8. — P. 1029-1037.
35. *Kuz'min V.E., Artemenko A.G., Muratov E.N.* Hierarchical QSAR technology based on the Simplex representation of molecular structure // *J. Comput. Aided Mol. Des.* — 2008. — Vol. 22. — P. 403-421.
36. *Kuz'min V.E., Artemenko A.G., Lozitska R.N., Fedtchouk A.S., Lozitsky V.P., Muratov E.N., Mescheriakov A.K.* Investigation of anticancer activity by means of 4D QSAR based on simplex representation of molecular structure // *SAR and QSAR in Environ. Res.* — 2005. — Vol. 16. — P. 219-230.
37. DRAGON Software, Milano Chemometrics and QSAR Research Group, www.disat.unimib.it/chm.
38. *Todeschini R., Consonni V.* Handbook of Molecular Descriptors. — Wiley WCH, Weinheim, 2000.
39. *Seredenin S.B., Blednov Y.A., Andronati S.A., Pavlovsky V.I., Yavorsky A.S.* 1,4-Benzodiazepine derivative, which has a selective anxiolytic activity. — Patent № 2133248 RF (1999).
40. *Dekermendjian K., Kahnberg P., Witt M.-R., Sterner O., Nielsen M., Liljefors T.* Structure-activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABAA receptor complex // *J. Med. Chem.* — 1999. — Vol. 42. — P. 4343-4350.
41. *Anzini M., Cappelli A., Vomero S., Giorgi G., Langer T., Bruni G., Romeo M.R., Basile A.S.* Molecular basis of peripheral vs central benzodiazepine receptor selectivity in a new class of peripheral benzodiazepine receptor ligands related to alpidem // *J. Med. Chem.* — 1996. — Vol. 39. — P. 4275-4284.
42. *Makan S.Yu., Burenkova N.A., Kostenko E.A., Andronati S.A., Bitensky V.S.* Affinity for benzodiazepine receptors in the CNS and neurotropic properties of new 3-arylidene(hetarylidene) derivatives of 1,2-dihydro-3H-1,4-benzodiazepin-2-one // *Visnyk Psikhatrii ta Psikhofarmakoterapii.* — 2007. — Vol. 2, No. 12. — P. 118-122.
43. *Boyko I.A., Makan S.Yu., Smul'sky S.P., Andronati S.A.* Study of affinity for the benzodiazepine sites of GABA receptors of CNS and functional activity of potential hypnotic — cinazepam // *Odessa National University Herald: Chemistry — Visnik Odeskogo Natsionalnogo Universitetu: Khimiya.* — 2005. — Vol. 10, No. 1. — P. 49-57.
44. *Cheng Y.C., Prusoff W.H.* Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 % inhibition (IC_{50}) of an enzymatic reaction // *Biochem. Pharmacol.* — 1973. — Vol. 2. — P. 3099-3108.